ZUG, Switzerland, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ...
So should Oculis Holding (NASDAQ:OCS) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the ...
Oculis' main value driver appears to be OCS-01, which targets a respectable $4 billion DME TAM with its non-invasive eye drops. Eye injections are tough on patients, so this bodes well for OCS-01 ...
Oculis Holding AG issued 2.5 million treasury shares, maintaining 7.2% of total registered shares, under an ATM program. Oculis Holding AG, a biopharmaceutical company based in Zug, Switzerland ...
ZUG, Switzerland, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) ("Oculis" or the "Company"), a global biopharmaceutical company, has ...
ZUG, Switzerland, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of ...
Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly. So should Oculis Holding (NASDAQ:OCS) shareholders be worried about its cash burn? In this ...
(MENAFN- GlobeNewsWire - Nasdaq) ZUG, Switzerland, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the“Company”), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback